Vienna Insurance Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.82M | Hold |
30,400
| – | – | 2.4% | 12 |
|
|
2025
Q1 | $3.36M | Hold |
30,400
| – | – | 1.83% | 14 |
|
|
2024
Q4 | $4.15M | Hold |
30,400
| – | – | 2.42% | 11 |
|
|
2024
Q3 | $3.5M | Hold |
30,400
| – | – | 1.49% | 21 |
|
|
2024
Q2 | $4.19M | Hold |
30,400
| – | – | 1.64% | 17 |
|
|
2024
Q1 | $4.19M | Hold |
30,400
| – | – | 1.64% | 19 |
|
|
2023
Q4 | $4.01M | Hold |
30,400
| – | – | 1.84% | 19 |
|
|
2023
Q3 | $3.42M | Hold |
30,400
| – | – | 1.52% | 17 |
|
|
2023
Q2 | $2.87M | Hold |
30,400
| – | – | 1.33% | 19 |
|
|
2023
Q1 | $3.08M | Sell |
30,400
-15,000
| -33% | -$1.52M | 1.81% | 18 |
|
|
2022
Q4 | $5.42M | Hold |
45,400
| – | – | 4.2% | 11 |
|
|
2022
Q3 | $4.82M | Hold |
45,400
| – | – | 3.4% | 8 |
|
|
2022
Q2 | $4.43M | Hold |
45,400
| – | – | 3% | 13 |
|
|
2022
Q1 | $4.26M | Hold |
45,400
| – | – | 2.39% | 15 |
|
|
2021
Q4 | $3.87M | Hold |
45,400
| – | – | 2.64% | 19 |
|
|
2021
Q3 | $4.35M | Hold |
45,400
| – | – | 2.32% | 15 |
|
|
2021
Q2 | $4.42M | Buy |
45,400
+14,400
| +46% | +$1.4M | 2.77% | 14 |
|
|
2021
Q1 | $3.01M | Buy |
+31,000
| New | +$3.01M | 2.88% | 14 |
|